Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: A prospective quantified sensory assessment study

Pain

Volumn 144, Issue 3, 2009, Pages 245-252

  Attal, N ^a,b   Bouhassira, D ^a,b   Gautron, M ^a,b   Vaillant, J N ^a   Mitry, E ^a,b   Lepere C ^a   Rougier, P ^a,b   Guirimand, F ^a  

^a HÔPITAL AMBROISE PARÉ   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

Cisplatin; Cold hyperalgesia; Neuropathic pain symptom inventory; Neuropathy; Oxaliplatin; Quantitative sensory testing

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ALLODYNIA; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; COLD; COLORECTAL CANCER; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DISEASE MARKER; DISEASE SEVERITY; DRUG WITHDRAWAL; DYSESTHESIA; DYSPHAGIA; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; GALLBLADDER CANCER; HEAT; HUMAN; HYPERALGESIA; JAW CRAMP; LUNG CANCER; MALE; MECHANICAL STIMULATION; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NEUROPATHIC PAIN; NEUROPATHOLOGY; NEUROPATHY; NEUROTOXICITY; PAIN ASSESSMENT; PAIN THRESHOLD; PANCREAS CANCER; PARESTHESIA; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROVOCATION TEST; QUANTITATIVE SENSORY TESTING; SENSORY ANALYSIS; SENSORY EVALUATION; STIMULUS RESPONSE; TEMPERATURE; THERMAL STIMULATION; TREATMENT DURATION; VIBRATION; VISUAL ANALOG SCALE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARCINOMA; COLD TEMPERATURE; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOT TEMPERATURE; HUMANS; HYPERALGESIA; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; TEMPERATURE SENSE;

EID: 67649494335     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2009.03.024     Document Type: Article

References (40)

1. Aaronson N.K., Ahmedzai S., Bergman B., Kaasa S., and Sullivan M. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993) 365-376
2. Adelsberger H., Quasthoff S., Grosskreutz J., Lepier A., Eckel F., and Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 406 (2000) 25-32
3. André T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., Topham C., Zaninelli M., Clingan P., Bridgewater J., Tabah-Fisch I., and de Gramont A. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 350 (2004) 2343-2351
4. Argyriou A.A., Chroni E., Polychronopoulos P., Iconomou G., Koutras A., Makatsoris T., Gerolymos M.K., Gourzis P., Assimakopoulos K., and Kalofonos H.P. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 67 (2006) 2253-2255
5. Argyriou A.A., Polychronopoulos P., Iconomou G., Koutras A., Makatsoris T., Gerolymos M.K., Gourzis P., Assimakopoulos K., Kalofonos H.P., and Chroni E. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncol 46 (2007) 1131-1137
6. Authier N., Gillet J.P., Fialip J., Eschalier A., and Coudore F. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp Neurol 182 (2003) 12-20
7. Baron R. Peripheral neuropathic pain: from mechanisms to symptoms. Clin J Pain 16 (2000) S12-S20
8. Binder A., Stengel M., Maag R., Wasner G., Schoch R., and Moosig F. Pain in oxaliplatin-induced neuropathy - sensitisation in the peripheral and central nociceptive system. Eur J Cancer 43 (2007) 2658-2663
9. Bouhassira D., Attal N., Fermanian J., Alchaar H., Gautron M., and Masquelier E. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 108 (2004) 248-257
10. Cavaletti G., Bogliun G., Marzorati L., Zincone A., Piatti M., Colombo N., Parma G., Lissoni A., Fei F., Cundari S., and Zanna C. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology 61 (2003) 1297-1300
11. Cersosimo R.J. Oxaliplatin-associated neuropathy: a review. Clin Cancer Res 13 (2007) 6359-6368
12. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., Boni C., Cortes-Funes H., Cervantes A., Freyer G., Papamichael D., Le Bail N., Louvet C., Hendler D., de Braud F., Wilson C., Morvan F., and Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
13. Ducreux D., Attal N., Parker F., and Bouhassira D. Mechanisms of central neuropathic pain: a combined psychophysical and fMRI study in syringomyelia. Brain 129 (2006) 963-976
14. Gamelin E., Gamelin L., Bossi L., and Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29 (2002) 21-33
15. Gamelin L., Boisdron-Celle M., Morel A., Poirier A.L., Berger V., Gamelin E., Tournigand C., and de Gramont A. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 26 (2008) 1188-1189
16. Gamelin L., Capitain O., Morel A., Dumont A., Traore S., Le Bouil A., Gilles S., Boisdron-Celle M., and Gamelin E. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res 13 (2007) 6359-6368
17. Grolleau F., Gamelin L., Boisdron-Celle M., Lapied B., Pelhate M., and Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. Ann Pharmacother 39 (2005) 128-135
18. Grothey A. Oxaliplatin-safety profile: neurotoxicity. J Neurophysiol 85 (2001) 2293-2297
19. Hansson P., Backonja M., and Bouhassira D. Usefulness and limitations of quantitative sensory testing: clinical and research application in neuropathic pain states. Pain 129 (2007) 256-259
20. Hatem S., Attal N., Willer J.C., and Bouhassira D. Psychophysical study of the effects of topical application of menthol in healthy volunteers. Pain 122 (2006) 190-196
21. Holmes J., Stanko J., Varchenko M., Ding H., Madden V.J., and Bagnell C.R. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci 46 (1998) 342-351
22. Jamieson S.M., Liu J., Connor B., and McKeage M.J. Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother Pharmacol 56 (2005) 391-399
23. Joseph E.K., Chen X., Bogen O., and Levine J.D. Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. J Pain 9 (2008) 463-472
24. Kiernan M.C., and Krishnan A.V. The pathophysiology of oxaliplatin-induced neurotoxicity. Curr Med Chem 13 (2006) 2901-2907
25. Kim H., Mittal D.P., Iadarola M.J., and Dionne R.A. Genetic predictors for acute experimental cold and heat pain sensitivity in humans. J Med Genet 43 (2006) e40
26. Krarup-Hansen A., Helweg-Larsen S., Schmalbruch H., Rørth M., and Krarup C. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 130 (2007) 1076-1088
27. + channel function in vivo. Clin Cancer Res 12 (2006) 4481-4484
28. Krishnan A.V., Goldstein D., Friedlander M., and Kiernan M.C. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 32 (2005) 51-60
29. Lecomte T., Landi B., Beaune P., Laurent-Puig P., and Loriot M.A. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 12 (2006) 3050-3056
30. Lehky T.J., Leonard G.D., Wilson R.H., Grem J.L., and Floeter M.K. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29 (2004) 387-392
31. Leonard G.D., Wright M.A., Quinn M.G., Fioravanti S., Harold N., and Schuler B. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 5 (2005) 116
32. Ling B., Authier N., Balayssac D., Eschalier A., and Coudore F. Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain 128 (2007) 225-234
33. Luo F.R., Wyrick S.D., and Chaney S.G. Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model. Cancer Chemother Pharmacol 44 (1999) 29-38
34. McKemy D.D., Neuhausser W.M., and Julius D. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 416 (2002) 52-58
35. Merskey H., and Bogduk N. Classification of chronic pain - descriptions of chronic pain syndromes and definition for terms (1994), IASP Press, Seattle
36. Pasetto L.M., D'Andrea M.R., Rossi E., and Monfardini S. Oxaliplatin-related neurotoxicity: how and why?. Crit Rev Oncol Hematol 59 (2006) 159-168
37. Postma T.J., and Heimans J.J. Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 11 (2000) 509-513
38. Ta L.E., Espeset L., Podratz J., and Windebank A.J. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 27 (2006) 992-1002
39. Webster R.G., Brain K.L., Wilson R.H., Grem J.L., and Vincent A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol 146 (2005) 1027-1039
40. Wilson R.H., Lehky T., Thomas R.R., Quinn M.G., Floeter M.K., and Grem J.L. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20 (2002) 1767-1774